Indeed, cancer cells can either become hypersensitive to residual estradiol (E2), remaining dependent on ER signaling for their proliferation[25], or possibly elude the inhibitory action of AIs by activating E2 in a ER-independent way. Here, ESR1 is linked to cancer.